TR201100149A2 - Geliştirilmiş risedronat formülasyonu. - Google Patents

Geliştirilmiş risedronat formülasyonu.

Info

Publication number
TR201100149A2
TR201100149A2 TR2011/00149A TR201100149A TR201100149A2 TR 201100149 A2 TR201100149 A2 TR 201100149A2 TR 2011/00149 A TR2011/00149 A TR 2011/00149A TR 201100149 A TR201100149 A TR 201100149A TR 201100149 A2 TR201100149 A2 TR 201100149A2
Authority
TR
Turkey
Prior art keywords
risedronate
formulation
improved
pharynx
larynx
Prior art date
Application number
TR2011/00149A
Other languages
English (en)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2011/00149A priority Critical patent/TR201100149A2/tr
Priority to TR2012/00211A priority patent/TR201200211A2/tr
Priority to EP12706950.8A priority patent/EP2661258B1/en
Priority to TR2012/00212A priority patent/TR201200212A2/tr
Priority to PCT/TR2012/000011 priority patent/WO2012093980A1/en
Priority to PCT/TR2012/000005 priority patent/WO2012093974A1/en
Priority to TR2012/00213A priority patent/TR201200213A2/tr
Priority to EP12706949.0A priority patent/EP2661262B1/en
Publication of TR201100149A2 publication Critical patent/TR201100149A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Packages (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Mevcut buluş kemik erimesi ve ilişkili hastalıkların önlenmesinde ve tedavisinde kullanılmak üzere risedronat ve/veya farmasötik açıdan uygun herhangi bir türevini içeren, ağız, bukkal kavite, farinks, larinks ve özafagusun epiteliyal ve mukozal tabakasını erezyon, ülser ve benzeri irritasyonlardan komyan, biyoyararlanımı yüksek formülasyonlara ilişkindir.
TR2011/00149A 2011-01-06 2011-01-06 Geliştirilmiş risedronat formülasyonu. TR201100149A2 (tr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
TR2011/00149A TR201100149A2 (tr) 2011-01-06 2011-01-06 Geliştirilmiş risedronat formülasyonu.
TR2012/00211A TR201200211A2 (tr) 2011-01-06 2012-01-06 Risedronat içeren farmasötik granüller.
EP12706950.8A EP2661258B1 (en) 2011-01-06 2012-01-06 Improved risedronate formulation
TR2012/00212A TR201200212A2 (tr) 2011-01-06 2012-01-06 Risedronat içeren geliştirilmiş formülasyonlar.
PCT/TR2012/000011 WO2012093980A1 (en) 2011-01-06 2012-01-06 Improved risedronate formulation
PCT/TR2012/000005 WO2012093974A1 (en) 2011-01-06 2012-01-06 Improved bisphosphonate formulations
TR2012/00213A TR201200213A2 (tr) 2011-01-06 2012-01-06 Kombine dozaj formları.
EP12706949.0A EP2661262B1 (en) 2011-01-06 2012-01-06 Improved bisphosphonate formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2011/00149A TR201100149A2 (tr) 2011-01-06 2011-01-06 Geliştirilmiş risedronat formülasyonu.

Publications (1)

Publication Number Publication Date
TR201100149A2 true TR201100149A2 (tr) 2012-07-23

Family

ID=45787321

Family Applications (4)

Application Number Title Priority Date Filing Date
TR2011/00149A TR201100149A2 (tr) 2011-01-06 2011-01-06 Geliştirilmiş risedronat formülasyonu.
TR2012/00211A TR201200211A2 (tr) 2011-01-06 2012-01-06 Risedronat içeren farmasötik granüller.
TR2012/00212A TR201200212A2 (tr) 2011-01-06 2012-01-06 Risedronat içeren geliştirilmiş formülasyonlar.
TR2012/00213A TR201200213A2 (tr) 2011-01-06 2012-01-06 Kombine dozaj formları.

Family Applications After (3)

Application Number Title Priority Date Filing Date
TR2012/00211A TR201200211A2 (tr) 2011-01-06 2012-01-06 Risedronat içeren farmasötik granüller.
TR2012/00212A TR201200212A2 (tr) 2011-01-06 2012-01-06 Risedronat içeren geliştirilmiş formülasyonlar.
TR2012/00213A TR201200213A2 (tr) 2011-01-06 2012-01-06 Kombine dozaj formları.

Country Status (3)

Country Link
EP (1) EP2661258B1 (tr)
TR (4) TR201100149A2 (tr)
WO (1) WO2012093980A1 (tr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL77243A (en) 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
TR200900878A2 (tr) * 2009-02-05 2010-08-23 Bi̇lgi̇ç Mahmut Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar

Also Published As

Publication number Publication date
EP2661258B1 (en) 2016-04-27
TR201200213A2 (tr) 2012-07-23
TR201200211A2 (tr) 2012-07-23
WO2012093980A1 (en) 2012-07-12
TR201200212A2 (tr) 2012-07-23
EP2661258A1 (en) 2013-11-13

Similar Documents

Publication Publication Date Title
CY1124219T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν τοπικο αναiσθητiκο οπως η βουπιβακαϊνη για τοπικη χορηγηση στο στομα ή τον φαρυγγα
MX2010007683A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
MY155564A (en) Arginine salts and their uses for the treatment of illnesses in the oral cavity
WO2013072932A3 (en) Oral care compositions
MX2010009851A (es) Oblea gingival.
CY1116057T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
WO2008086014A3 (en) Bis-aryl amide derivatives useful for the treatment of cancer
CY1116695T1 (el) Συνθεση περιεχοντας υπερ-μικρονοποιημενο παλμιτοϋλ-αιθανολαμιδιο
MX2011003473A (es) Composiciones para el cuidado bucal.
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
MX348823B (es) Formulaciones estables de linaclotida.
CY1116775T1 (el) Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης
EP2849738C0 (en) HIGH PENETRATION PRODRUG COMPOSITIONS AND ASSOCIATED PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PULMONARY CONDITIONS
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
MX2011011109A (es) Formulaciones orales de bendamustina.
TW201129560A (en) 4-[2-[[5-methyl-1-(2-naphtalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine salts
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
IL210953A0 (en) Compositions for the prophylaxis and treatment of dermatological/mucosal diseases, and uses thereof
MX389399B (es) Una formulación de rapamicina inhalable para el tratamiento de hipertensión pulmonar.
IN2014MN02245A (tr)
TR200900878A2 (tr) Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar
TR200900879A2 (tr) Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler
UA109879C2 (uk) Похідні нітрилу, їх застосування у фармацевтичних цілях і в композиції
CY1111805T1 (el) Υποκατεστημενες κινολονες ιιι
CY1117795T1 (el) Φαρμακευτικες συνθεσεις απαλλαγμενες κιτρικου αλατος οι οποιες περιεχουν ανακινρα